PATENT CLAIM ANALYSIS

Application Number: 16298868
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "345000"]

Abstract:
Provided herein are pyridinethiones, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative, inflammatory, neurodegenerative, or immune-mediated disease (e.g., multiple sclerosis).

Claim (Index 1):
A pharmaceutical composition comprising a compound of Formula I: or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient; wherein:\n R 1  is hydrogen or deuterium; \n R 3  and R 5  are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (c) \u2014C(O)R 1a , \u2014C(O)OR 1a , \u2014C(O)NR 1b R 1c , \u2014C(O)SR 1a , \u2014C(NR 1a )NR 1b R 1c , \u2014C(S)R 1a , \u2014C(S)OR 1a , \u2014C(S)NR 1b R 1c , \u2014OR 1a , \u2014OC(O)R 1a , \u2014OC(O)OR 1a , \u2014OC(O)NR 1b R 1c , \u2014OC(O)SR 1a , \u2014OC(\u2550NR 1a )NR 1b R 1c , \u2014OC(S)R 1a , \u2014OC(S)OR 1a , \u2014OC(S)NR 1b R 1c , \u2014OS(O)R 1a , \u2014OS(O) 2 R 1a , \u2014OS(O)NR 1b R 1c , \u2014OS(O) 2 NR 1b R 1c , \u2014NR 1b R 1c , \u2014NR 1a C(O)R 1d , \u2014NR 1a C(O)OR 1d , \u2014NR 1a C(O)NR 1b R 1c , \u2014NR 1a C(O)SR 1d , \u2014NR 1a C(\u2550NR 1d )NR 1b R 1c , \u2014NR 1a C(S)R 1d , \u2014NR 1a C(S)OR 1d , \u2014NR 1a C(S)NR 1b R 1c , \u2014NR 1a S(O)R 1d , \u2014NR 1a S(O) 2 R 1d , \u2014NR 1a S(O)NR 1b R 1c , \u2014NR 1a S(O) 2 NR 1b R 1c , \u2014SR 1a , \u2014S(O)R 1a , \u2014S(O) 2 R 1a , \u2014S(O)NR 1b R 1c , or \u2014S(O) 2 NR 1b R 1c ; \n R 4  is (i) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (ii) \u2014C(O)R 1a , \u2014C(O)OR 1a , \u2014C(O)NR 1b R 1c , \u2014C(O)SR 1a , \u2014C(NR 1a )NR 1b R 1c , \u2014C(S)R 1a , \u2014C(S)OR 1a , or \u2014C(S)NR 1b R 1c ; \n R 6  is C 1-10  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; and \n each R 1a , R 1b , R 1c , and R 1d  is independently hydrogen, deuterium, C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or R 1a  and R 1c  together with the C and N atoms to which they are attached form heterocyclyl; or R 1b  and R 1c  together with the N atom to which they are attached form heterocyclyl; \n wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, where each Q is independently selected from (a) deuterium, cyano, halo, and nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; and (c) \u2014C(O)R a , \u2014C(O)OR a , \u2014C(O)NR b R c , \u2014C(O)SR a , \u2014C(NR a )NR b R c , \u2014C(S)R a , \u2014C(S)OR a , \u2014C(S)NR b R c , \u2014OR a , \u2014OC(O)R a , \u2014OC(O)OR a , \u2014OC(O)NR b R c , \u2014OC(O)SR a , \u2014OC(\u2550NR a )NR b R c , \u2014OC(S)R a , \u2014OC(S)OR a , \u2014OC(S)NR b R c , \u2014OS(O)R a , \u2014OS(O) 2 R a , \u2014OS(O)NR b R c , \u2014OS(O) 2 NR b R c , \u2014NR b R c , \u2014NR a C(O)R d , \u2014NR a C(O)OR d , \u2014NR a C(O)NR b R c , \u2014NR a C(O)SR d , \u2014NR a C(\u2550NR d )NR b R c , \u2014NR a C(S)R d , \u2014NR a C(S)OR d , \u2014NR a C(S)NR b R c , \u2014NR a S(O)R d , \u2014NR a S(O) 2 R d , \u2014NR a S(O)NR b R c , \u2014NR a S(O) 2 NR b R c , \u2014SR a , \u2014S(O)R a , \u2014S(O) 2 R a , \u2014S(O)NR b R c , and \u2014S(O) 2 NR b R c , wherein each R a , R b , R c , and R d  is independently (i) hydrogen or deuterium; (ii) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; or (iii) R b  and R c  together with the N atom to which they are attached form heterocyclyl, optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; \n wherein each Q a  is independently selected from: (a) deuterium, cyano, halo, and nitro; (b) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, and heterocyclyl; and (c) \u2014C(O)R e , \u2014C(O)OR e , \u2014C(O)NR f R g , \u2014C(O)SR e , \u2014C(NR e )NR f R g , \u2014C(S)R e , \u2014C(S)OR e , \u2014C(S)NR f R g , \u2014OR e , \u2014OC(O)R e , \u2014OC(O)OR e , \u2014OC(O)NR f R g , \u2014OC(O)SR e , \u2014OC(\u2550NR e )NR f R g , \u2014OC(S)R e , \u2014OC(S)OR e , \u2014OC(S)NR f R g , \u2014OS(O)R e , \u2014OS(O) 2 R e , \u2014OS(O)NR f R g , \u2014OS(O) 2 NR f R g , \u2014NR f R g , \u2014NR e C(O)R h , \u2014NR e C(O)OR f , \u2014NR e C(O)NR f R g , \u2014NR e C(O)SR f , \u2014NR e C(\u2550NR h )NR f R g , \u2014NR e C(S)R h , \u2014NR e C(S)OR f , \u2014NR e C(S)NR f R g , \u2014NR e S(O)R h , \u2014NR e S(O) 2 R h , \u2014NR e S(O)NR f R g , \u2014NR e S(O) 2 NR f R g , \u2014SR e , \u2014S(O)R e , \u2014S(O) 2 R e , \u2014S(O)NR f R g , and \u2014S(O) 2 NR f R g ; wherein each R e , R f , R g , and R h  is independently (i) hydrogen or deuterium; (ii) C 1-6  alkyl, C 2-6  alkenyl, C 2-6  alkynyl, C 3-10  cycloalkyl, C 6-14  aryl, C 7-15  aralkyl, heteroaryl, or heterocyclyl; or (iii) R f  and R g  together with the N atom to which they are attached form heterocyclyl.

Metadata:
- Claim Count in Document: 34.0
- Percentile: 99.0
- Lexical Diversity: 1.4359
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15595199', '15282687', '16040461', '13431716', '14729700']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8511922834893493
- 35 USC 102 Novelty (BERT): 0.609024824114914
- Combined Prediction Score: 0.8269755375519058
- Mean Citation Score: 540.534274
- Max Citation Score: 576.4785
- Similarity Product: 484.7343150909841

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test